Acadia has advertised two new positions, seemingly related to its intended launch of DayBue in Europe.
Directors of Value Access and Policy are being sought for both Germany and France, the No. 1 and 2 top value pharma markets in Europe. It is stated that responsibility for additional markets may possibly be added to these roles “as we expand the business footprint across the European continent.”
Successful candidates will be required to “ensure pricing and access launch strategies are of high quality and are fit-for-purpose” as well as “develop pricing & access strategy incorporating additional evidence needs, value proposition beyond the drug, managed entry schemes and other agreements to ensure mutual value, and pricing strategy.”
Acadia is targeting candidates with 5 years’ leadership experience in Market Access within a pharmaceutical/biotech organization and significant scientific exposure within rare disease, ideally in the CNS realm, and in the context of early patient access programs.
More specifically, they are seeking people with “recent experience in early patient access programs and launch of orphan drugs ideally with direct or adjacent experience within the CNS space and hands-on experience in pricing negotiations”, in Germany and France respectively.
With an estimated German population of 84 million and a French population of 68 million, these two European markets represent a third of the European population and a possible Rett population of slightly less than half of that in the United States.
The total Rett syndrome population across Europe and the UK is estimated to be roughly 50% higher than that within the United States.
Catherine Owen Adams, CEO of Acadia, stated last month that the company intends to initiate a Managed Access Program for DayBue in selected European countries in the second quarter of this year. It would appear that Germany and France will be leading the way.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)